openPR Logo
Press release

Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report

06-12-2017 10:47 AM CET | Health & Medicine

Press release from: Pharmaceutical Market Reports - MRH

Market Research HUB

Market Research HUB

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1135789

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 4, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Browse Full Report with TOC - http://www.marketresearchhub.com/report/anaplastic-astrocytoma-pipeline-review-h2-2017-report.html

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Make an Enquiry - http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1135789

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report here

News-ID: 572171 • Views: 156

More Releases from Pharmaceutical Market Reports - MRH

Global Active Pharmaceutical Ingredients Market Size, Growth, Share, Trends and …
Market Research Hub includes new market research report "Global Active Pharmaceutical Ingredients Market Research Report 2017-2022 by Players, Regions, Product Types & Applications" to its huge collection of research reports. The global Active Pharmaceutical Ingredients market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Request Free Sample Report -
Global and Chinese Carfentanil Expedient Market Outlook and Profitable Forecasts …
The carfentanil market is witnessing huge developments in the veterinary and other chemical research sectors. Looking into this development, a new report has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Global and Chinese Carfentanil Market Outlook 2017-2022‘’. The study offers a precise evaluation of the most positive business factors such as biggest players and regions; as well as a prospective forecast till
Global Propofol Sales Market Size, Share, Growth, Trends and Forecast
According to the report "Global Propofol Sales Market Report 2017" added by Market Research HUB, the global Propofol market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate
Global Mammalian Cell Culture Sales Market Size, Share, Trends and Forecast
According to the report "Global Mammalian Cell Culture Sales Market Report 2017" added by Market Research HUB, the global Mammalian Cell Culture market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market

All 5 Releases


More Releases for Anaplastic

Anaplastic Oligoastrocytoma Therapeutics Pipeline Review 2018
Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. The disease can be treated by surgical methods
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Oligoastrocytoma Therapeutics Pipeline Analysis - Clinical Trials , R …
Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/anaplastic-oligoastrocytoma-therapeutics-pipeline-analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Oligoastrocytoma Market to Register Substantial Expansion by 2024
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear to
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,